Lenvatinib Plus Sintilimab vs. Lenvatinib for Advanced HCC Treated With TACE
Status:
Recruiting
Trial end date:
2026-10-31
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib plus sintilimab
(Len-Sin) compared with lenvatinib (Len) alone as maintenance therapy for patients with
advanced hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE).
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University